Topic: clinical benefit

This panel examines why strong immunogenicity in cancer-vaccine development does not always translate into clinical benefit. Prasun Chakraborty, Nora Disis and Timothy Spear compare delivery strategies aimed at the immune system or the tumour and discuss trade-offs between platforms. The programme considers how manufacturing limits and combination regimens constrain feasible approaches, and how delivery decisions influence immune activation, clinical translation and production at scale.

Uncertainty regarding which psychological mechanisms are fundamental in mediating SSRI treatment outcomes and wide-ranging variability in their efficacy has raised more questions than it has solved. Since subjective mood states are an abstract scientific construct, only available through self-report in humans, and likely involving input from multiple top-down and bottom-up signals, it has been difficult to model at what level SSRIs interact with this process. Converging translational evidence indicates a role for serotonin in modulating context-dependent parameters of action selection, affect,